Affiliation:
1. National Cheng Kung University Hospital
Abstract
Abstract
Background
[223Ra]RaCl2 is an important treatment modality for bone-dominant metastatic castration-resistant prostate cancer (mCRPC). However, there is currently a lack of effective markers to monitor treatment response during the course of treatment. We retrospectively collected data from mCRPC patients who underwent [223Ra]RaCl2 treatment at our institution between August 2020 and June 2023. Prostate specific antigen (PSA) measurements prior to treatment and during treatment were collected. Baseline PSADT was calculated from PSA measurements prior to [223Ra]RaCl2 treatment; interim PSADT was calculated from PSA measurements before [223Ra]RaCl2 treatment and prior to the 4th course injection. Overall survival was calculated from start of treatment to the date of death. Univariable and multivariable analysis using the Cox proportional hazards model were performed to examine the association of factors with overall survival.
Results
We included 35 patients from our institution, with a median overall survival of 13.3 months. Eighteen (51.4%) completed all six courses of treatment. PSADT response (interim PSADT > baseline PSADT or decreased PSA) was observed in 20 patients. Overall survival was associated with a PSADT response (HR = 0.318, 95% CI 0.133–0.762, p = 0.010) when compared to patients without a PSADT response.
Conclusions
Dynamic changes in PSADT were associated with survival in mCRPC patients receiving [223Ra]RaCl2 therapy. Comparing interim and baseline PSADT could serve as a valuable marker for determining treatment benefit.
Publisher
Research Square Platform LLC
Reference25 articles.
1. 1. SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute 2023 Apr 19. [updated: 2023 Jun 8
2. cited 2023 Oct 16]: https://seer.cancer.gov/statistics-network/explorer/.
3. 2. Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, et al. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. Prostate. 2014;74(2):210-6.
4. 3. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213 − 23.
5. 4. Nilsson S, Cislo P, Sartor O, Vogelzang NJ, Coleman RE, O'Sullivan JM, et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol. 2016;27(5):868 − 74.